Butinib 140 mg (Capsule)
Unit Price: ৳ 500.00 (3 x 10: ৳ 15,000.00)
Strip Price: ৳ 5,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibrutinib |
| Company | Drug international ltd |
Indications
- Treatment of Mantle Cell Lymphoma
- Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Treatment of Waldenstrom Macroglobulinemia (WM)
- Treatment of Marginal Zone Lymphoma
- Patients with 17p deletion Chronic Lymphocytic Leukemia
- Patients requiring systemic therapy
- Patients who have received anti-CD 20-based therapy
Pharmacology
- Small-molecule inhibitor of BTK
- Forms a covalent bond with a cysteine residue
- Inhibits BTK enzymatic activity
- Signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways
- Inhibits malignant B-cell proliferation and survival
- Inhibits cell migration and substrate adhesion
Dosage
- Recommended dose for Mantle Cell Lymphoma is 560 mg once daily
- Recommended dose for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia (WM) is 420 mg once daily
- Dose when used in combination with bendamustine and rituximab
Administration
- Administer orally once daily at the same time each day
- Swallow the capsules whole with water
- Avoid opening, breaking, or chewing the capsules
Interaction
- Co-administration with CYP3A inhibitors should be avoided
- Butinib dose should be reduced if a moderate CYP3A inhibitor must be used
- Co-administration with strong CYP3A inducers should be avoided
Contraindications
- Hypersensitivity to the active substance or excipients
Side Effects
- Hemorrhage
- Infections
- Cytopenias
- Atrial Fibrillation
- Hypertension
- Second Primary Malignancies
- Tumor Lysis Syndrome
- Diarrhea
- Visual Disturbance
Pregnancy & Lactation
- Potential fetal harm
- Need to apprise patients of potential hazard to the fetus
- Unknown risk of major birth defects and miscarriage
- No information on presence in human milk or effects on breastfed infant
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- No overall differences in effectiveness observed between younger and older patients
- Increased occurrence of anemia and pneumonia in older patients
- Increase in Butinib exposure in hepatic impairment
- Safety not evaluated in cancer patients with mild to severe hepatic impairment
- Monitor patients for signs of Butinib toxicity
Overdose Effects
- Limited specific experience in the management of Butinib overdose
- Reversible Grade 4 hepatic enzyme increases observed in one case
- Closely monitor patients who ingest more than the recommended dosage
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store below 30°C
- Protect from light
- Keep out of the reach of children